Ubamatamab + REGN7075 + Sarilumab
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Non-Small Cell Lung Cancer
Conditions
Advanced/Metastatic Non-Small Cell Lung Cancer
Trial Timeline
Mar 18, 2026 → Jun 10, 2030
NCT ID
NCT07154290About Ubamatamab + REGN7075 + Sarilumab
Ubamatamab + REGN7075 + Sarilumab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Advanced/Metastatic Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07154290. Target conditions include Advanced/Metastatic Non-Small Cell Lung Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Non-Small Cell Lung Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07154290 | Phase 2 | Recruiting |
Competing Products
20 competing products in Advanced/Metastatic Non-Small Cell Lung Cancer